Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 20, 2021

Building Biotech Series with Tom Jarvie

One of the greatest unexplored spaces of the world is the microbiome, a bustling network of trillions of microorganisms living inside each of us. If we could learn more about them, the advancements we’d make in healthcare and other fields would be incredible. This line of thinking is what spurred Tom Jarvie and Mark Driscoll to found Shoreline Biome, maker of the most complete end-to-end microbiome sample prep kits on the market. Hear their incredible story in this Building Biotechs podcast.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.